(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.40%) $78.07
(0.18%) $2.21
(-0.07%) $2 322.50
(0.11%) $27.58
(-0.20%) $986.40
(0.17%) $0.931
(0.38%) $10.94
(0.17%) $0.801
(0.00%) $91.45
Live Chart Being Loaded With Signals
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas...
Stats | |
---|---|
今日成交量 | 417 000 |
平均成交量 | 1.39M |
市值 | 1.12B |
EPS | HKD0 ( 2024-03-27 ) |
下一个收益日期 | ( HKD0 ) 2024-06-06 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.35 |
ATR14 | HKD0.0100 (0.68%) |
音量 相关性
HBM Holdings Limited 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
HBM Holdings Limited 相关性 - 货币/商品
HBM Holdings Limited 财务报表
Annual | 2023 |
营收: | HKD89.50M |
毛利润: | HKD87.47M (97.73 %) |
EPS: | HKD0.0300 |
FY | 2023 |
营收: | HKD89.50M |
毛利润: | HKD87.47M (97.73 %) |
EPS: | HKD0.0300 |
FY | 2022 |
营收: | HKD40.66M |
毛利润: | HKD40.53M (99.68 %) |
EPS: | HKD-0.190 |
FY | 2021 |
营收: | HKD4.31M |
毛利润: | HKD4.17M (96.82 %) |
EPS: | HKD-0.179 |
Financial Reports:
No articles found.
HBM Holdings Limited
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。